Actinium’s stock jumps 22% on new data for its acute myeloid leukemia therapy

Shares of Actinium Pharmaceuticals Inc. were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for relapsed or refractory acute myeloid leukemia. Actinium said it plans to share additional clinical data by the end of the year. The company’s stock has soared 99.1% this year, while the S&P 500 is down 18.5%.

pt the field of bone marrow conditioning with Iomab-B, first in r/r AML and then by building upon its robust prior clinical results in several hematological diseases. We look forward to sharing additional clinical data from the SIERRA trial by year end.”

fdsup://factset/Doc%20Viewer%20Single?_expand=oV0Mn8&float_window=true

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.